Evaro Raises $25M to Embed NHS-Licensed Healthcare Into Consumer Apps and Retail Brands

April 2, 2025

Evaro, the NHS-licensed digital healthcare platform founded by emergency physician Dr Thuria Wenbar and pharmacist researcher Dr Oskar Wenbar, raised $25 million (£18.3 million) in a Series A funding round led by AlbionVC, with participation from Simplyhealth Ventures, Exceptional Ventures, Cornerstone VC, and BBI. The capital will accelerate Evaro's healthcare-as-a-service model across its three target markets: consumer brands seeking new revenue streams, healthcare providers expanding digital capacity, and employers deploying health benefits. The company will use funds to expand into new treatment areas including longevity medicine and advanced diagnostics, grow its clinical and engineering teams, and continue developing its API-first platform.

General practice in the UK is under severe structural strain. In 2024, 20.5 million people waited at least a month for a GP appointment — a 60% increase over seven years. For conditions that are common, low-complexity, and treatable without in-person consultation — contraception, erectile dysfunction, hair loss, skin conditions, weight management — the NHS is an increasingly difficult route to care. Meanwhile, millions of patients are already engaging with health-adjacent consumer brands: period-tracking apps, sexual wellness retailers, fitness platforms, and employee benefit programmes. These brands have trusted relationships with users, but no regulatory infrastructure to deliver clinical services. Evaro was built specifically to close this gap.

Founded in 2018, Evaro has spent seven years constructing a regulatory stack that is, by the company's own account, unique in the UK market: simultaneous CQC (Care Quality Commission), GPhC (General Pharmaceutical Council), and NHS licensing, plus seven total regulatory approvals. This regulatory depth is the core moat. It means consumer brands can embed a full clinical pathway — asynchronous consultation, NHS GP record access, remote diagnostics, prescribing, dispensing, and aftercare — under their own brand, in as little as two weeks of technical integration. Evaro currently supports over 80 conditions, has a 4.5 Trustpilot rating, and has served more than two million patients. Live partners include period-tracking app Clue and sexual wellness retailer Lovehoney, both of which use Evaro's API to offer prescription services directly within their user experiences.

The funding will support Evaro's ambition to reach 10 million patients over the next three years, onboard additional consumer brand and healthcare provider partners, and expand its product scope. The employer benefits channel represents a particularly significant commercial opportunity: companies are under increasing pressure to provide genuinely useful health benefits to employees, and Evaro's infrastructure enables deployment of personalised prescription services into benefit programmes with no clinical or regulatory burden on the employer.

AlbionVC partner Christoph Ruedig, who joins Evaro's board, framed the investment in terms of an established category analogy: embedded finance transformed banking by distributing financial services through non-financial platforms; Evaro is now attempting to do the same for healthcare. The comparison is apt, but the regulatory complexity of healthcare means the barriers to replication are meaningfully higher than they were in fintech, suggesting Evaro's seven-year head start in building its licensing stack is a more durable competitive advantage than it might initially appear.

Sources